US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Bicara Therapeutics

17.60

-0.0400-0.23%

Post-market: 18.000.4000+2.27%19:58 EST

Volume:2.76M

Turnover:48.73M

Market Cap:964.16M

PE:-7.90

High:18.38

Open:17.80

Low:17.50

Close:17.64

52wk High:19.75

52wk Low:7.80

Shares:54.78M

Float Shares:24.13M

Volume Ratio:3.12

T/O Rate:11.45%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2271

EPS(LYR):-4.0460

ROE:-26.64%

ROA:-18.59%

PB:2.39

PE(LYR):-4.35

Loading ...

Overview Company News Filings

U.S. RESEARCH ROUNDUP-Autozone, Coursera, Lennar

President and COO Ryan Cohlhepp Reports Disposal of Bicara Therapeutics Inc. Common Shares

How Breakthrough Status For Ficerafusp Combo At Bicara Therapeutics (BCAX) Has Changed Its Investment Story

Simply Wall St.

Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12

Bicara Therapeutics Advances Dose Optimization of Potential Neck, Head Cancer Treatment

MT Newswires Live

Bicara Therapeutics (BCAX): Assessing Valuation After Breakthrough Therapy Designation and Early Trial Data Progress

Simply Wall St.

Bicara Therapeutics Advances Ficerafusp Alfa to Pivotal Study Dose Selection for Head and Neck Cancer

Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

Bicara Therapeutics Reports Positive Early Data for Ficerafusp Alfa Plus Pembrolizumab in Head and Neck Cancer Trial

Bicara Therapeutics CFO Ivan Hyep Reports Disposal of Common Shares

Bicara Therapeutics Chief Medical Officer David Raben Reports Disposal of Common Shares

Bicara Therapeutics (BCAX): A Fresh Valuation Check After Q3 Earnings Reveal Sharp Shift in Losses

Simply Wall St.

Stock Track | Bicara Therapeutics Soars 5.03% as Multiple Analysts Boost Price Targets

Stock Track | Bicara Therapeutics Soars 5% as Multiple Analysts Boost Price Targets

Bicara Therapeutics Is Maintained at Equal-Weight by Wells Fargo

H.C. Wainwright Remains a Buy on Bicara Therapeutics Inc. (BCAX)

Promising Drug Pipeline and Upcoming Trial Data Support Buy Rating for Bicara Therapeutics

Bicara Therapeutics Q3 EPS $(0.67) Misses $(0.54) Estimate

Bicara Therapeutics reports Q3 EPS (67c), consensus (53c)

Bicara Therapeutics reports third quarter net loss of $36.3 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BCAX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCAX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":17.6,"timestamp":1766178000000,"preClose":17.64,"halted":0,"volume":2762814,"hourTrading":{"tag":"盘后","latestPrice":18,"preClose":17.6,"latestTime":"19:58 EST","volume":350423,"amount":6168184.4581,"timestamp":1766192328338},"delay":0,"floatShares":24134001,"shares":54781950,"eps":-2.227112,"marketStatus":"Not Yet Opened","change":-0.04,"latestTime":"12-19 16:00:00 EST","open":17.8,"high":18.38,"low":17.5,"amount":48733729.247496,"amplitude":0.049887,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.227112,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766394000000},"marketStatusCode":0,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":17.64,"preHourTrading":{"tag":"盘前","latestPrice":17.76,"preClose":17.64,"latestTime":"09:29 EST","volume":121,"amount":2161.619988,"timestamp":1766154599505},"postHourTrading":{"tag":"盘后","latestPrice":18,"preClose":17.6,"latestTime":"19:58 EST","volume":350423,"amount":6168184.4581,"timestamp":1766192328338},"volumeRatio":3.1160790680447272,"impliedVol":0.1375,"impliedVolPercentile":0.088},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","floatShares":24134001,"roa":"-18.59%","roe":"-26.64%","lyrEps":-4.045991,"volumeRatio":3.1160790680447272,"shares":54781950,"dividePrice":0,"high":18.38,"amplitude":0.049887,"preClose":17.64,"low":17.5,"week52Low":7.8,"pbRate":"2.39","week52High":19.75,"institutionHeld":0,"latestPrice":17.6,"eps":-2.227112,"divideRate":0,"volume":2762814,"delay":0,"ttmEps":-2.227112,"open":17.8,"prevYearClose":17.42,"prevWeekClose":18.48,"prevMonthClose":18.56,"prevQuarterClose":15.79,"fiveDayClose":18.48,"twentyDayClose":16.18,"sixtyDayClose":10.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCAX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-10","symbol":"BCAX","fiscalQuarterEnding":"2025/09","expectedEps":-0.55,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.67},{"market":"US","date":"2025-08-12","symbol":"BCAX","fiscalQuarterEnding":"2025/06","expectedEps":-0.54,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-0.5},{"market":"US","date":"2025-05-13","symbol":"BCAX","fiscalQuarterEnding":"2025/03","expectedEps":-0.4,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-03-27","symbol":"BCAX","fiscalQuarterEnding":"2024/12","expectedEps":-0.31,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"pre","actualEps":-0.39},{"market":"US","date":"2024-11-12","symbol":"BCAX","fiscalQuarterEnding":"2024/09","expectedEps":-0.46,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.6}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCAX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCAX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2222,"buy":0.6667,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":9,"updateTime":1757394000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BCAX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BCAX","date":"2025-12-19","current":-7.902611,"percent":0.666667,"low":-22.704836,"twenty":-16.525595,"median":-9.707395,"eighty":-6.409029,"high":-5.144536,"avg":-11.075313,"sd":4.863928,"marketCap":966353598},"quantilePoints":[{"date":"2024-09-13","current":-12.837909,"twenty":-12.837909,"median":-12.837909,"eighty":-12.837909,"marketCap":832435719},{"date":"2024-09-20","current":-20.633135,"twenty":-21.391361,"median":-20.283845,"eighty":-14.007791,"marketCap":1337893755},{"date":"2024-09-27","current":-21.555755,"twenty":-21.594337,"median":-21.446718,"eighty":-19.006626,"marketCap":1397718272},{"date":"2024-10-04","current":-19.962139,"twenty":-21.575885,"median":-21.337681,"eighty":-19.559541,"marketCap":1294385015},{"date":"2024-10-11","current":-15.936161,"twenty":-21.540658,"median":-20.570229,"eighty":-18.732598,"marketCap":1033332575},{"date":"2024-10-18","current":-17.143955,"twenty":-21.466848,"median":-20.283845,"eighty":-16.808457,"marketCap":1111648307},{"date":"2024-10-25","current":-18.964032,"twenty":-21.403103,"median":-19.23243,"eighty":-16.959431,"marketCap":1229665764},{"date":"2024-10-31","current":-19.878264,"twenty":-21.362844,"median":-19.23243,"eighty":-17.02653,"marketCap":1288946422},{"date":"2024-11-08","current":-19.79439,"twenty":-21.337681,"median":-19.82794,"eighty":-17.143955,"marketCap":1283507830},{"date":"2024-11-15","current":-20.345116,"twenty":-21.127995,"median":-19.949558,"eighty":-18.418848,"marketCap":1210086831},{"date":"2024-11-22","current":-16.257533,"twenty":-21.102833,"median":-19.82794,"eighty":-17.143955,"marketCap":966965549},{"date":"2024-11-29","current":-19.02049,"twenty":-20.975343,"median":-19.458892,"eighty":-17.009755,"marketCap":1131300719},{"date":"2024-12-06","current":-17.876882,"twenty":-20.695202,"median":-19.01323,"eighty":-17.12047,"marketCap":1063281195},{"date":"2024-12-13","current":-16.509127,"twenty":-20.532485,"median":-19.005969,"eighty":-17.12047,"marketCap":981929844},{"date":"2024-12-20","current":-15.187116,"twenty":-20.493904,"median":-18.892739,"eighty":-16.769874,"marketCap":903299275},{"date":"2024-12-27","current":-17.49263,"twenty":-20.458153,"median":-18.854995,"eighty":-16.764842,"marketCap":1040426635},{"date":"2025-01-03","current":-15.484454,"twenty":-20.399979,"median":-18.727694,"eighty":-16.641786,"marketCap":920984351},{"date":"2025-01-10","current":-13.952019,"twenty":-20.332862,"median":-18.565256,"eighty":-16.325863,"marketCap":829838189},{"date":"2025-01-17","current":-10.868852,"twenty":-20.271506,"median":-18.306879,"eighty":-15.951961,"marketCap":646457553},{"date":"2025-01-24","current":-10.951191,"twenty":-20.22215,"median":-18.224539,"eighty":-15.55307,"marketCap":651354959},{"date":"2025-01-31","current":-11.811185,"twenty":-20.138275,"median":-17.666458,"eighty":-14.949245,"marketCap":702505641},{"date":"2025-02-07","current":-11.52757,"twenty":-20.11652,"median":-17.561246,"eighty":-13.156068,"marketCap":685636799},{"date":"2025-02-14","current":-12.003311,"twenty":-19.978914,"median":-17.49263,"eighty":-12.003311,"marketCap":713932921},{"date":"2025-02-21","current":-12.643731,"twenty":-19.965494,"median":-17.085242,"eighty":-11.997822,"marketCap":752023854},{"date":"2025-02-28","current":-11.307997,"twenty":-19.942009,"median":-16.815614,"eighty":-11.891694,"marketCap":672577050},{"date":"2025-03-07","current":-14.409462,"twenty":-19.890007,"median":-16.73236,"eighty":-11.891694,"marketCap":857045999},{"date":"2025-03-14","current":-12.213735,"twenty":-19.838005,"median":-16.60519,"eighty":-11.893524,"marketCap":726448513},{"date":"2025-03-21","current":-11.975864,"twenty":-19.8011,"median":-16.394587,"eighty":-11.882546,"marketCap":712300452},{"date":"2025-03-28","current":-10.745093,"twenty":-19.525992,"median":-16.092853,"eighty":-11.882546,"marketCap":730612568},{"date":"2025-04-04","current":-9.486153,"twenty":-19.364339,"median":-15.936742,"eighty":-11.721526,"marketCap":645010946},{"date":"2025-04-11","current":-8.139007,"twenty":-19.311424,"median":-15.55307,"eighty":-11.500123,"marketCap":553411758},{"date":"2025-04-17","current":-9.430022,"twenty":-19.133936,"median":-15.269456,"eighty":-11.355571,"marketCap":641194313},{"date":"2025-04-25","current":-12.533268,"twenty":-19.02049,"median":-15.045308,"eighty":-11.297018,"marketCap":852199585},{"date":"2025-05-02","current":-11.795546,"twenty":-19.011777,"median":-14.409462,"eighty":-11.329955,"marketCap":802038125},{"date":"2025-05-09","current":-10.531076,"twenty":-18.980807,"median":-14.002338,"eighty":-11.242349,"marketCap":716060542},{"date":"2025-05-16","current":-8.546663,"twenty":-18.933837,"median":-13.265854,"eighty":-11.091295,"marketCap":789139074},{"date":"2025-05-23","current":-9.249533,"twenty":-18.888545,"median":-12.837909,"eighty":-10.95668,"marketCap":854037173},{"date":"2025-05-30","current":-5.575709,"twenty":-18.86506,"median":-12.634583,"eighty":-10.80298,"marketCap":514821897},{"date":"2025-06-06","current":-6.514837,"twenty":-18.854995,"median":-12.506498,"eighty":-10.643069,"marketCap":601534484},{"date":"2025-06-13","current":-6.833787,"twenty":-18.81138,"median":-12.341819,"eighty":-10.421008,"marketCap":630984042},{"date":"2025-06-20","current":-5.569802,"twenty":-18.738652,"median":-12.190862,"eighty":-10.145292,"marketCap":514276535},{"date":"2025-06-27","current":-5.203601,"twenty":-18.705007,"median":-12.094799,"eighty":-9.441248,"marketCap":480464080},{"date":"2025-07-03","current":-5.333543,"twenty":-18.687321,"median":-12.003311,"eighty":-9.12531,"marketCap":492462048},{"date":"2025-07-11","current":-5.859219,"twenty":-18.443191,"median":-11.975864,"eighty":-8.617541,"marketCap":540999282},{"date":"2025-07-18","current":-6.881039,"twenty":-18.418848,"median":-11.920971,"eighty":-8.339475,"marketCap":635346939},{"date":"2025-07-25","current":-7.04642,"twenty":-18.306879,"median":-11.898098,"eighty":-7.625808,"marketCap":650617080},{"date":"2025-08-01","current":-6.562089,"twenty":-18.251986,"median":-11.884376,"eighty":-7.016887,"marketCap":605897381},{"date":"2025-08-08","current":-6.0246,"twenty":-18.224539,"median":-11.847781,"eighty":-6.881039,"marketCap":556269423},{"date":"2025-08-15","current":-6.063601,"twenty":-17.876882,"median":-11.795546,"eighty":-6.786535,"marketCap":622562015},{"date":"2025-08-22","current":-6.180515,"twenty":-17.675607,"median":-11.648291,"eighty":-6.638873,"marketCap":634565840},{"date":"2025-08-29","current":-6.329315,"twenty":-17.657309,"median":-11.619058,"eighty":-6.514837,"marketCap":649843436},{"date":"2025-09-05","current":-6.409029,"twenty":-17.584119,"median":-11.52757,"eighty":-6.407746,"marketCap":658027862},{"date":"2025-09-12","current":-6.366515,"twenty":-17.562161,"median":-11.3858,"eighty":-6.401771,"marketCap":653662835},{"date":"2025-09-19","current":-5.877601,"twenty":-17.506353,"median":-11.36289,"eighty":-6.371769,"marketCap":603465021},{"date":"2025-09-26","current":-5.686286,"twenty":-17.49263,"median":-11.294273,"eighty":-6.328252,"marketCap":583822398},{"date":"2025-10-03","current":-8.880173,"twenty":-17.49263,"median":-11.226216,"eighty":-6.328252,"marketCap":911745073},{"date":"2025-10-10","current":-9.712715,"twenty":-17.21369,"median":-11.089726,"eighty":-6.337818,"marketCap":997223830},{"date":"2025-10-17","current":-9.936118,"twenty":-17.050015,"median":-11.051829,"eighty":-6.344195,"marketCap":1020161070},{"date":"2025-10-24","current":-8.999952,"twenty":-16.959431,"median":-10.928319,"eighty":-6.362264,"marketCap":924043110},{"date":"2025-10-31","current":-8.755273,"twenty":-16.841022,"median":-10.759065,"eighty":-6.371769,"marketCap":898921371},{"date":"2025-11-07","current":-7.749959,"twenty":-16.783048,"median":-10.701761,"eighty":-6.376332,"marketCap":795703789},{"date":"2025-11-14","current":-6.428441,"twenty":-16.754777,"median":-10.617258,"eighty":-6.376332,"marketCap":781190607},{"date":"2025-11-21","current":-7.293982,"twenty":-16.72193,"median":-10.425573,"eighty":-6.385646,"marketCap":886371951},{"date":"2025-11-28","current":-8.366891,"twenty":-16.703998,"median":-10.156917,"eighty":-6.394149,"marketCap":1016752992},{"date":"2025-12-05","current":-8.457052,"twenty":-16.641786,"median":-10.005266,"eighty":-6.400929,"marketCap":1027709382},{"date":"2025-12-12","current":-8.497624,"twenty":-16.572254,"median":-9.798232,"eighty":-6.406463,"marketCap":1032639757},{"date":"2025-12-19","current":-7.952153,"twenty":-16.525595,"median":-9.707395,"eighty":-6.409029,"marketCap":966353598}],"updateTime":1766384673591},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCAX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2592927648","title":"U.S. RESEARCH ROUNDUP-Autozone, Coursera, Lennar","url":"https://stock-news.laohu8.com/highlight/detail?id=2592927648","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592927648?lang=en_us&edition=fundamental","pubTime":"2025-12-18 14:42","pubTimestamp":1766040152,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Autozone, Coursera, LennarDec 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Autozone, Courser","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nL4N3XO0FW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4147","CLW","CMI","ALL","CPT","ASH","ALSN","AMRZ","COUR","SG9999001176.USD","AMAT","ALB","LU0345769631.USD","CE","IE00B7SZLL34.SGD","ACHC","AZO","ACAD","BIIB","DG","ARDT","BAC","AAL","LU1989763690.USD","BK4107","DOW","BK4090","APD","DAL","LU0234570918.USD","SGXZ57979304.SGD","CLYM","CRL","BRO","CL","AXTA","CF","AVTX","CTVA","ACM","BK4548","AJG","CBT","BTSG","BCAX","BBNX","DD","CGNX","HOUS","BSX"],"gpt_icon":0},{"id":"2592307249","title":"President and COO Ryan Cohlhepp Reports Disposal of Bicara Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592307249","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592307249?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:52","pubTimestamp":1765921958,"startTime":"0","endTime":"0","summary":"Ryan Cohlhepp, President and COO of Bicara Therapeutics Inc., reported a disposal of common shares of Bicara Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 16, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDLbFfP3q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"President and COO Ryan Cohlhepp Reports Disposal of Bicara Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2591672522","title":"How Breakthrough Status For Ficerafusp Combo At Bicara Therapeutics (BCAX) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2591672522","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591672522?lang=en_us&edition=fundamental","pubTime":"2025-12-16 08:36","pubTimestamp":1765845384,"startTime":"0","endTime":"0","summary":"Earlier this month, Bicara Therapeutics reported preliminary Phase 1b data showing that weekly 750 mg ficerafusp alfa plus pembrolizumab was generally well tolerated in first-line HPV-negative recurrent or metastatic head and neck squamous cell carcinoma, and the FDA granted the combination Breakthrough Therapy Designation in this setting.\nNew biomarker findings suggesting stronger TGF-β inhibition and immune activation at the 1,500 mg dose level add scientific weight to Bicara’s ongoing...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcax/bicara-therapeutics/news/how-breakthrough-status-for-ficerafusp-combo-at-bicara-thera","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcax/bicara-therapeutics/news/how-breakthrough-status-for-ficerafusp-combo-at-bicara-thera","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2591649410","title":"Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649410","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591649410?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:00","pubTimestamp":1765803600,"startTime":"0","endTime":"0","summary":"BOSTON, Dec.  15, 2025  (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/15/3205352/0/en/Bicara-Therapeutics-to-Present-at-the-J-P-Morgan-2026-Annual-Healthcare-Conference-on-Monday-January-12.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574139.USD","LU0795875169.SGD","BCAX","LU0106831901.USD","LU1989772923.USD","IE00BKVL7J92.USD","LU0528227936.USD","LU0006306889.USD","IE00BZ1G4Q59.USD","LU2357305700.SGD","LU1732800096.USD","LU0158827781.USD","LU0158827948.USD","LU1244550221.USD","HCSG","LABU","LU0267386448.USD","LU1720051017.SGD","LU1720051108.HKD","LU1668664300.SGD","LU2023251221.USD","LU1363072403.SGD","XBI","LU1548497426.USD","BK4127","LU0029874061.USD","BK4585","LU1989772840.SGD","LU2028103732.USD","LU1244550494.USD","LU1732799900.SGD","LU0314104364.USD","LU1791710400.SGD","BK4137","BK4588","LU0234570918.USD","LU1791710582.SGD","LU0128526141.USD","LU2111349929.HKD","BK4581","LU2133065610.SGD","XLV","BK4516","LU0098860793.USD","LU0795875086.SGD","LU0971096721.USD","LU2089283258.USD","LU2089284900.SGD","LU0557290698.USD","BK4504"],"gpt_icon":0},{"id":"2589337903","title":"Bicara Therapeutics Advances Dose Optimization of Potential Neck, Head Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2589337903","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589337903?lang=en_us&edition=fundamental","pubTime":"2025-12-08 19:57","pubTimestamp":1765195027,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (BCAX) said Saturday that preliminary data from a phase 1b study cohort evaluating a 750 milligram dose of its drug ficerafusp alfa weekly in combination with pembrolizumab was wel","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2589508874","title":"Bicara Therapeutics (BCAX): Assessing Valuation After Breakthrough Therapy Designation and Early Trial Data Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2589508874","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589508874?lang=en_us&edition=fundamental","pubTime":"2025-12-07 17:30","pubTimestamp":1765099831,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (BCAX) just put a spotlight on its lead cancer program, pairing early Phase 1b data with an FDA Breakthrough Therapy designation, a one two punch that immediately sharpens the stock’s long term narrative.\nSee our latest analysis for Bicara Therapeutics.\nThe Breakthrough Therapy news arrives after a powerful run, with Bicara’s 1 month share price return of 24.32 percent and 3 month share price return of 48.09 percent. However, the 1 year total shareholder return is still...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcax/bicara-therapeutics/news/bicara-therapeutics-bcax-assessing-valuation-after-breakthro","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcax/bicara-therapeutics/news/bicara-therapeutics-bcax-assessing-valuation-after-breakthro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","PRGS","BCAX","LU2065732104.USD","BK4097"],"gpt_icon":0},{"id":"2589825138","title":"Bicara Therapeutics Advances Ficerafusp Alfa to Pivotal Study Dose Selection for Head and Neck Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2589825138","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589825138?lang=en_us&edition=fundamental","pubTime":"2025-12-06 21:00","pubTimestamp":1765026022,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 06, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251206:nNDL6DMg1R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","BK4112","BK4139","LU0314104364.USD","NDAQ","SG9999014005.SGD","SG9999014013.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4585","BK4588","LU2095319765.USD","LU2210150020.SGD","LU2210149790.SGD","BCAX"],"gpt_icon":0},{"id":"2589825155","title":"Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2589825155","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589825155?lang=en_us&edition=fundamental","pubTime":"2025-12-06 21:00","pubTimestamp":1765026000,"startTime":"0","endTime":"0","summary":"Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study i","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201043/0/en/Bicara-Therapeutics-Preliminary-Phase-1b-Expansion-Cohort-Data-Evaluating-750mg-of-Ficerafusp-Alfa-Weekly-Plus-Pembrolizumab-Advances-Pivotal-Study-Dose-Selection-on-Track-for-Firs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPS","BK4139","BCAX","BK4124"],"gpt_icon":0},{"id":"2588724750","title":"Bicara Therapeutics Reports Positive Early Data for Ficerafusp Alfa Plus Pembrolizumab in Head and Neck Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724750","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724750?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590456,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 01, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL9hCKCp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BCAX","LU2210150020.SGD","BK4112","LU2095319765.USD","NDAQ","BK4139","IE00BKPKM429.USD","BK4588","LU2210149790.SGD","IE00B64PRP62.GBP","BK4585","LU0314104364.USD"],"gpt_icon":0},{"id":"2586407221","title":"Bicara Therapeutics CFO Ivan Hyep Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586407221","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586407221?lang=en_us&edition=fundamental","pubTime":"2025-11-26 07:42","pubTimestamp":1764114158,"startTime":"0","endTime":"0","summary":"Ivan Hyep, Chief Financial Officer of Bicara Therapeutics Inc., reported a disposal of common shares of Bicara Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL68hQYq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2586407231","title":"Bicara Therapeutics Chief Medical Officer David Raben Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586407231","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586407231?lang=en_us&edition=fundamental","pubTime":"2025-11-26 07:40","pubTimestamp":1764114022,"startTime":"0","endTime":"0","summary":"David Raben, Chief Medical Officer of Bicara Therapeutics Inc., reported a disposal of common shares of Bicara Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL20y0V0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara Therapeutics Chief Medical Officer David Raben Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2586163744","title":"Bicara Therapeutics (BCAX): A Fresh Valuation Check After Q3 Earnings Reveal Sharp Shift in Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2586163744","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586163744?lang=en_us&edition=fundamental","pubTime":"2025-11-25 07:14","pubTimestamp":1764026048,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (BCAX) just released its earnings report for the third quarter and nine months through September 2025, revealing sharp changes in both net loss and basic loss per share compared to last year.\nSee our latest analysis for Bicara Therapeutics.\nThe latest share price surge, up 11.5% in a single day and 19.9% over the past week, signals renewed momentum for Bicara Therapeutics. However, with a total shareholder return of -1.2% over the past year, longer-term investors have not...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcax/bicara-therapeutics/news/bicara-therapeutics-bcax-a-fresh-valuation-check-after-q3-ea","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcax/bicara-therapeutics/news/bicara-therapeutics-bcax-a-fresh-valuation-check-after-q3-ea","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BCAX"],"gpt_icon":0},{"id":"1124620838","title":"Stock Track | Bicara Therapeutics Soars 5.03% as Multiple Analysts Boost Price Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=1124620838","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124620838?lang=en_us&edition=fundamental","pubTime":"2025-11-11 23:24","pubTimestamp":1762874659,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (BCAX) stock is soaring 5.03% in Tuesday's trading session, buoyed by a series of positive analyst ratings and increased price targets. The biotechnology company has caught the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BCAX"],"gpt_icon":0},{"id":"1152698193","title":"Stock Track | Bicara Therapeutics Soars 5% as Multiple Analysts Boost Price Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=1152698193","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152698193?lang=en_us&edition=fundamental","pubTime":"2025-11-11 23:24","pubTimestamp":1762874657,"startTime":"0","endTime":"0","summary":"Shares of Bicara Therapeutics (BCAX) are soaring 5.03% in Tuesday's trading session, fueled by a series of positive analyst actions. The biotechnology company has caught the attention of Wall Street,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BCAX"],"gpt_icon":0},{"id":"2582367021","title":"Bicara Therapeutics Is Maintained at Equal-Weight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2582367021","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582367021?lang=en_us&edition=fundamental","pubTime":"2025-11-11 22:46","pubTimestamp":1762872360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2025 09:46 ET (14:46 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0162691827.USD","LU0310800965.SGD","LU0048573561.USD","LU0256863811.USD","IE00B19Z3B42.SGD","BK4559","LU2361044949.HKD","LU1814569148.SGD","LU0742534661.SGD","LU1267930227.SGD","LU0868494708.USD","BK4501","LU0942090050.USD","LU1035773651.USD","IE00B19Z3581.USD","LU0029864427.USD","LU0130517989.USD","LU0149725797.USD","LU0648001328.SGD","LU0106831901.USD","LU0251131958.USD","BK4139","LU0683600562.USD","BK4504","LU0868494617.USD","LU0310800379.SGD","LU0971096721.USD","LU0251142724.SGD","BK4207","LU1074936037.SGD","LU0708994859.HKD","LU1267930573.SGD","IE0002270589.USD","LU2461242641.AUD","LU0208291251.USD","LU1668664300.SGD","LU0320765489.SGD","LU1267930490.SGD","LU0640476718.USD","IE000M9KFDE8.USD","LU0289960550.SGD","LU1506573853.SGD","LU0267386448.USD","LU0175139822.USD","LU1280957306.USD","BCAX","LU0072461881.USD","LU1363072403.SGD","LU0070302665.USD"],"gpt_icon":0},{"id":"2582636518","title":"H.C. Wainwright Remains a Buy on Bicara Therapeutics Inc. (BCAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582636518","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582636518?lang=en_us&edition=fundamental","pubTime":"2025-11-11 19:56","pubTimestamp":1762862185,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Bicara Therapeutics Inc. today and set a price target of $40.00. Burns covers the H...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-bicara-therapeutics-inc-bcax-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-bicara-therapeutics-inc-bcax-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2582318388","title":"Promising Drug Pipeline and Upcoming Trial Data Support Buy Rating for Bicara Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2582318388","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582318388?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:15","pubTimestamp":1762809314,"startTime":"0","endTime":"0","summary":"Analyst Soumit Roy of JonesTrading maintained a Buy rating on Bicara Therapeutics Inc., retaining the price target of $27.00. Soumit Roy has given ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-drug-pipeline-and-upcoming-trial-data-support-buy-rating-for-bicara-therapeutics-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-drug-pipeline-and-upcoming-trial-data-support-buy-rating-for-bicara-therapeutics-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"gpt_icon":0},{"id":"2582876166","title":"Bicara Therapeutics Q3 EPS $(0.67) Misses $(0.54) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582876166","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582876166?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:41","pubTimestamp":1762778517,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.54) by 23.84 percent. This is a 58.13 percent increase over losses of $(1.60) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48748932/bicara-therapeutics-q3-eps-0-67-misses-0-54-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX"],"gpt_icon":0},{"id":"2582787696","title":"Bicara Therapeutics reports Q3 EPS (67c), consensus (53c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582787696","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582787696?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:37","pubTimestamp":1762778236,"startTime":"0","endTime":"0","summary":"“The FDA’s recent Breakthrough Therapy Designation for ficerafusp alfa in first-line HPV-negative HNSCC represents an important milestone for Bicar...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-reports-q3-eps-67c-consensus-53c-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-reports-q3-eps-67c-consensus-53c-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"gpt_icon":0},{"id":"2582875706","title":"Bicara Therapeutics reports third quarter net loss of $36.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582875706","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582875706?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:30","pubTimestamp":1762777834,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLl0gsJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B3QW5Z07.USD","BK4139","LU0314104364.USD","IE00BGHQF748.EUR","LU2210149790.SGD","LU2095319765.USD","BK4585","IE00BKPKM429.USD","BK4112","BCAX","BK4588","IE00B64PRP62.GBP","NDAQ"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":52,"code":"91000000","status":"200"}]}}